- December 14, 2020NEW YORK, December 14, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- December 2, 2020Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente Deutschland, 02. Dezember 2020 – „Wir können lebenswichtige Medikamente zur…
- November 24, 2020NEW YORK, November 24, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- November 17, 2020– Initial Appointments Include Internationally Recognized Experts: Fred D. Lublin, M.D.; Bruce E. Sands, M.D., M.S.; Jerrold R. Turner, M.D., Ph.D.…
- November 10, 2020NEW YORK, November 10, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- November 5, 2020– Released Very Positive Phase 2 Data for IMU-838 in Relapsing-Remitting Multiple Sclerosis; Company to Submit End-of-Phase 2 Meeting Requests…
- November 2, 2020– Top-Line Data Expected in Q1 2021 – NEW YORK, November 2, 2020 – Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company…
- October 20, 2020EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy Luxembourg, Gräfelfing, Germany…
- September 29, 2020NEW YORK, September 29, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- September 28, 2020NEW YORK, September 28, 2020 – Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
